| Tumour evolution in hepatocellular carcinoma AJ Craig, J Von Felden, T Garcia-Lezana, S Sarcognato, A Villanueva Nature reviews Gastroenterology & hepatology 17 (3), 139-152, 2020 | 714 | 2020 |
| β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma M Ruiz de Galarreta, E Bresnahan, P Molina-Sánchez, KE Lindblad, ... Cancer discovery 9 (8), 1124-1141, 2019 | 713 | 2019 |
| Intratumoral heterogeneity and clonal evolution in liver cancer B Losic, AJ Craig, C Villacorta-Martin, SN Martins-Filho, N Akers, X Chen, ... Nature communications 11 (1), 291, 2020 | 310 | 2020 |
| Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice H Schuett, R Oestreich, GH Waetzig, W Annema, M Luchtefeld, A Hillmer, ... Arteriosclerosis, thrombosis, and vascular biology 32 (2), 281-290, 2012 | 279 | 2012 |
| GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis J Best, LP Bechmann, JP Sowa, S Sydor, A Dechêne, K Pflanz, S Bedreli, ... Clinical gastroenterology and hepatology 18 (3), 728-735. e4, 2020 | 263 | 2020 |
| Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score B Scheiner, K Pomej, MM Kirstein, F Hucke, F Finkelmeier, O Waidmann, ... Journal of hepatology 76 (2), 353-363, 2022 | 201 | 2022 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 184 | 2022 |
| Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ... Gastroenterology 154 (4), 976-988. e4, 2018 | 179 | 2018 |
| Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis J Hartl, H Ehlken, M Sebode, M Peiseler, T Krech, R Zenouzi, ... Journal of hepatology 68 (4), 754-763, 2018 | 146 | 2018 |
| Liquid biopsy in the clinical management of hepatocellular carcinoma J von Felden, T Garcia-Lezana, K Schulze, B Losic, A Villanueva Gut 69 (11), 2025-2034, 2020 | 138 | 2020 |
| Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort B Scheiner, MM Kirstein, F Hucke, F Finkelmeier, K Schulze, J von Felden, ... Alimentary pharmacology & therapeutics 49 (10), 1323-1333, 2019 | 138 | 2019 |
| Heterozygous carriage of the alpha1-antitrypsin Pi* Z variant increases the risk to develop liver cirrhosis P Strnad, S Buch, K Hamesch, J Fischer, J Rosendahl, R Schmelz, ... Gut 68 (6), 1099-1107, 2019 | 130 | 2019 |
| Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis F Stickel, S Buch, HD Nischalke, KH Weiss, D Gotthardt, J Fischer, ... Official journal of the American College of Gastroenterology| ACG 113 (10 …, 2018 | 116 | 2018 |
| Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals JD Debes, M van Tilborg, ZMA Groothuismink, BE Hansen, JS Zur Wiesch, ... Gastroenterology 154 (3), 515-517. e3, 2018 | 115 | 2018 |
| Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma J von Felden, AJ Craig, T Garcia-Lezana, I Labgaa, PK Haber, D D’Avola, ... Oncogene 40 (1), 140-151, 2021 | 114 | 2021 |
| A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma I Labgaa, C Villacorta-Martin, D D’Avola, AJ Craig, J von Felden, ... Oncogene 37 (27), 3740-3752, 2018 | 114 | 2018 |
| Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers F Stickel, P Lutz, S Buch, HD Nischalke, I Silva, V Rausch, J Fischer, ... Hepatology 72 (1), 88-102, 2020 | 111 | 2020 |
| The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study J von Felden, L Alric, S Pischke, C Aitken, S Schlabe, U Spengler, ... Journal of hepatology 71 (3), 465-472, 2019 | 89 | 2019 |
| High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma D D’Avola, C Villacorta-Martin, SN Martins-Filho, A Craig, I Labgaa, ... Scientific reports 8 (1), 11570, 2018 | 83 | 2018 |
| Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection J von Felden, K Schulze, T Krech, F Ewald, B Nashan, K Pantel, ... Oncotarget 8 (52), 89978, 2017 | 83 | 2017 |
